1-3 of 3
Erik Verner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance

Eleni Venetsanakos, Ken A. Brameld, Vernon T. Phan, Erik Verner, Timothy D. Owens, Yan Xing, Danny Tam, Jacob LaStant, Kwan Leung, Dane E. Karr, Ronald J. Hill, Mary E. Gerritsen, David M. Goldstein, Jens Oliver Funk, J. Michael Bradshaw
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (12): 2668–2676.
https://doi.org/10.1158/1535-7163.MCT-17-0309
Published: 03 December 2017
View article titled, The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance
Open the PDF for The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance in another window
Includes: Supplementary data
Journal Articles

CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo

Z. Alexander Cao, Kathryn E. Bass, Sriram Balasubramanian, Liang Liu, Brian Schultz, Erik Verner, YuQin Dai, Rafael A. Molina, Jack R. Davis, Shawn Misialek, Martin Sendzik, Christine J. Orr, Ling Leung, Ondine Callan, Peter Young, Stacie A. Dalrymple, Joseph J. Buggy
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (7): 1693–1701.
https://doi.org/10.1158/1535-7163.MCT-06-0042
Published: 04 August 2006
View article titled, CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity <em>in vitro</em> and <em>in vivo</em>
Open the PDF for CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity <em>in vitro</em> and <em>in vivo</em> in another window
Journal Articles

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo

Joseph J. Buggy, Z. Alexander Cao, Kathryn E. Bass, Erik Verner, Sriram Balasubramanian, Liang Liu, Brian E. Schultz, Peter R. Young, Stacie A. Dalrymple
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (5): 1309–1317.
https://doi.org/10.1158/1535-7163.MCT-05-0442
Published: 26 May 2006
View article titled, CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity <em>in vitro</em> and <em>in vivo</em>
Open the PDF for CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity <em>in vitro</em> and <em>in vivo</em> in another window